现代医药卫生
現代醫藥衛生
현대의약위생
MODERN MEDICINE HEALTH
2014年
19期
2908-2910
,共3页
丁宝军%刘成%刘多%刘学军%穆家贵
丁寶軍%劉成%劉多%劉學軍%穆傢貴
정보군%류성%류다%류학군%목가귀
电外科手术%尿道%膀胱肿瘤%多柔比星/类似物和衍生物%肿瘤浸润%经尿道膀胱肿瘤气化电切术%膀胱灌注化疗
電外科手術%尿道%膀胱腫瘤%多柔比星/類似物和衍生物%腫瘤浸潤%經尿道膀胱腫瘤氣化電切術%膀胱灌註化療
전외과수술%뇨도%방광종류%다유비성/유사물화연생물%종류침윤%경뇨도방광종류기화전절술%방광관주화료
Electrosurgery%Urethra%Urinary bladder neoplasms%Doxorubicin/analogs&derivatives%Neoplasm invasiveness%Transurethral reseection of bladdercancer%Bladder irrigation
目的:探讨经尿道二次气化电切联合盐酸吡柔比星(THP)膀胱灌注治疗高危非肌层浸润性膀胱尿路上皮癌的疗效。方法选取2007年6月至2012年3月该院收治的已行第1次经尿道膀胱肿瘤电切术的高危非肌层浸润性膀胱尿路上皮癌患者68例,所有患者术后1周内给予盐酸THP 30 mg膀胱灌注,每周1次,连续10周。术后6周将患者随机分为对照组和治疗组,各34例。对照组患者继续采用盐酸THP膀胱灌注化疗,治疗组患者行第2次经尿道气化电切术,术后采用盐酸THP膀胱灌注。随访2年,观察比较两组患者肿瘤复发率。结果治疗组患者膀胱肿瘤的复发率[14.71%(5/34)]较对照组[35.29%(12/34)]显著降低,差异有统计学意义(P<0.05)。至随访截止时,治疗组继续随访肿瘤复发率[27.27%(9/33)]显著低于对照组[71.88%(23/32)],差异有统计学意义(P<0.05),但两组进展为肌层浸润肿瘤的发生率比较,差异无统计学意义(P>0.05)。结论经尿道二次气化电切联合THP膀胱灌注治疗高危非肌层浸润性膀胱尿路上皮癌,可显著降低肿瘤复发率,改善患者预后。
目的:探討經尿道二次氣化電切聯閤鹽痠吡柔比星(THP)膀胱灌註治療高危非肌層浸潤性膀胱尿路上皮癌的療效。方法選取2007年6月至2012年3月該院收治的已行第1次經尿道膀胱腫瘤電切術的高危非肌層浸潤性膀胱尿路上皮癌患者68例,所有患者術後1週內給予鹽痠THP 30 mg膀胱灌註,每週1次,連續10週。術後6週將患者隨機分為對照組和治療組,各34例。對照組患者繼續採用鹽痠THP膀胱灌註化療,治療組患者行第2次經尿道氣化電切術,術後採用鹽痠THP膀胱灌註。隨訪2年,觀察比較兩組患者腫瘤複髮率。結果治療組患者膀胱腫瘤的複髮率[14.71%(5/34)]較對照組[35.29%(12/34)]顯著降低,差異有統計學意義(P<0.05)。至隨訪截止時,治療組繼續隨訪腫瘤複髮率[27.27%(9/33)]顯著低于對照組[71.88%(23/32)],差異有統計學意義(P<0.05),但兩組進展為肌層浸潤腫瘤的髮生率比較,差異無統計學意義(P>0.05)。結論經尿道二次氣化電切聯閤THP膀胱灌註治療高危非肌層浸潤性膀胱尿路上皮癌,可顯著降低腫瘤複髮率,改善患者預後。
목적:탐토경뇨도이차기화전절연합염산필유비성(THP)방광관주치료고위비기층침윤성방광뇨로상피암적료효。방법선취2007년6월지2012년3월해원수치적이행제1차경뇨도방광종류전절술적고위비기층침윤성방광뇨로상피암환자68례,소유환자술후1주내급여염산THP 30 mg방광관주,매주1차,련속10주。술후6주장환자수궤분위대조조화치료조,각34례。대조조환자계속채용염산THP방광관주화료,치료조환자행제2차경뇨도기화전절술,술후채용염산THP방광관주。수방2년,관찰비교량조환자종류복발솔。결과치료조환자방광종류적복발솔[14.71%(5/34)]교대조조[35.29%(12/34)]현저강저,차이유통계학의의(P<0.05)。지수방절지시,치료조계속수방종류복발솔[27.27%(9/33)]현저저우대조조[71.88%(23/32)],차이유통계학의의(P<0.05),단량조진전위기층침윤종류적발생솔비교,차이무통계학의의(P>0.05)。결론경뇨도이차기화전절연합THP방광관주치료고위비기층침윤성방광뇨로상피암,가현저강저종류복발솔,개선환자예후。
Objective To probe the clinic effects of second transurethral resection combined with intravesical instillation with pirarubicin hydrochloride THP in treatment of high-risk non-muscle invasive uroepithelium cell carcinoma of bladder (NMI-UCCB). Methods A total of 68 patients with high-risk NMIUCCB who had first transurethral resection in this hospital from Jun. 2007 to Mar. 2012 were treated with intravesical instillation with 30 mg pirarubicin hydrochloride in a week after operation ,once for a week,lasting 10 weeks continuously. At 6 weeks after the operation,the patients were randomly divided into the control group and the treatment group,34 of each group. The patients in the control group were treated with chemotherapy of intravesical instil-lation with pirarubicin hydrochloride while the treatment group with second transurethral resection combined with intravesical in-stillation. In the 2-year follow up,the tumor recurrence rate of the patients of the two groups were observed and compared. Results There was a significant reduction in the recurrence rate[14.71%(5/34)] of human bladder tumor in the treatment group compared with that [35.29%(12/34)]of the control group(P<0.05). Up to the lasted follow-up day,the recurrence rate[27.27%(9/33)] of human bladder tumor in the treatment group was obviously lower than that[71.88%(23/32)] of the control group during the follow-up(P<0.05),however,there was no significant difference in growing to be muscle invasive uroepithelium cell carcinoma of bladder between the two groups(P>0.05). Conclusion The treatment of second transurethral resection combined with intravesical instil-lation with pirarubicin hydrochloride in treatment of high-risk non-muscle invasive uroepithelium cell carcinoma of bladder may effectively decrease the recurrence rate of tumor and improve their prognosis conditions.